Five Prime Therapeutics, Inc.

Biomarin Pharmaceutical Inc.

Minmin Qin

Diane Hollenbaugh

Ernestine A Lee

Elizabeth Bosch

Ali Sadra

Lewis T Williams

Stephen Kohl Doberstein

Kevin Hestir

Justin Wong

Hongbing Zhang

Ge Wu

Christopher M Starr

Dan J Wendt

Paul Andrew Fitzpatrick

Lin Chen

Gary N Zecherle

Wai-Pan Chan

John M Henstrand

Emil D Kakkis

John M Hendstrand

Stuart Sweidler

Paul A Fitzpatrick

Stuart Swiedler

The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.

Methods of treating disease with FGFR1 fusion proteins

FGFR2 fusion proteins comprising C-terminal deletion mutants of FGFR2-IIIC

Polynucleotides encoding FGFR1-IIIc ECD fusion proteins

FGFR2-IIIb fusion proteins and methods of making them

ECD carboxy-terminal deletion FGFR4 fusion proteins and methods of producing them

FGFR3-IIIc fusion proteins

Compositions and methods of treating disease with FGFR fusion proteins

The present invention provides a highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase and biologically active mutants, fragments and analogs thereof as well as pharmaceutical formulations comprising highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase. The invention also provides methods for treating diseases caused all or in part by deficiencies in human N-acetylgalactosamine-4-sulfatase including MPS VI and methods for producing and purifying the recombinant precursor enzyme to a highly purified form.

Precursor of N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme

Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme

The present invention provides a recombinant human &agr;-L-iduronidase and biologically active fragments and mutants thereof, large scale methods to produce and purify commercial grade recombinant human &agr;-L-iduronidase enzyme as well as methods to treat certain genetic disorders including &agr;-L-iduronidase deficiency and mucopolysaccharidosis I (MPS 1).

Recombinant &agr;-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof

Growing community of inventors

Pleasanton, CA, United States of America

Minmin Qin